DM

Showing posts with label Likely. Show all posts
Showing posts with label Likely. Show all posts

Saturday, June 29, 2013

Understanding of complex diseases likely to improve following the unexpected discovery of the ways Cells Move

Main category: Cancer / Oncology
Also included in: respiratory / asthma;??Biology / biochemistry
Article Date: June 25, 2013 - 1:00 PDT current ratings for:
Understanding of complex diseases likely to improve following the unexpected discovery of the ways Cells Move
not yet ratednot yet rated
A new discovery about how cells move within the organization can provide scientists with crucial information about the mechanisms of diseases such as the spreading of the cancer or constriction of the Airways caused by asthma. Led by researchers from the Harvard School of Public Health (HSPH) and the Institute for bioengineering of Catalonia (IBEC), investigators found that the epithelial cells - the type that form a barrier between the inside and the outside of the body, such as skin cells - move group, powered by forces both of in and from neighbouring cells - to fill the empty spaces that they encounter.

The study appears in Nature Materials advanced online edition.

"We have tried to understand the fundamental relationship between cellular movements collective and collective forces of cell phones, which may occur during the invasion of the cancer cells, for example. But, in so doing, we are fallen on a phenomenon that was totally unexpected, "said lead author Jeffrey Fredberg, Professor of Bioengineering and physiology to the investigator HSPH Department of Environmental Health and co-Minister of HSPH molecular laboratory and integrative cellular dynamics.

Biologists, engineers and physicists at HSPH and IBEC worked together to shed light on the collective cell movement because it plays a key role in functions such as the healing of wounds, organ development and tumor growth. Using a technique called stress monolayer microscopy--which they invented themselves - they have measured the forces affecting a single layer of epithelial cells in motion. They examined cells speed and direction as traction - how certain cells either pull or push themselves and thus force the collective movement.

As they expected, the researchers found that when an obstacle was placed in the path of a layer of advanced cell - in this case, a gel that provided no traction - cells settled around him, closely hugging the sides of the gel as they passed. However, the researchers also found something amazing - cells, in addition to moving forward, continued to collectively back to frost, as if the desire to fill the space empty. Researchers have dubbed this movement "kenotaxis", Greek words "keno" (empty) and "taxi" (arrangement), because it seemed that cells are trying to fill a void.

This new discovery could help researchers to better understand the behaviour of the cell - and evaluate the potential influence that behavior - in a variety of complex diseases, such as cancer, asthma, cardiovascular diseases, developmental anomalies and glaucoma. The findings could also help with regenerative medicine and tissue engineering, which rely on cell migration.

In carcinomas, for example - who represent 90% of all cancers and involve epithelial cells - new information on cell movement could improve understanding of how cancer cells migrate through the body. Research on asthma could also get a boost, because scientists believe the migration of epithelial cells damaged in the lungs are involved in narrowing of the Airways caused by the disease.

"Kenotaxis is a property of the cell collective, not the individual cell," said Jae Hun Kim, first author of the study. "It was amazing to us that the collective cell can organize itself draw systematically in one direction while moving consistently in a quite different direction. ''

Article adapted by Medical News Today press release original. Click on "references" tab above for the source.
Visit our cancer / Oncology section for the latest news on this subject. Other authors HSPH included James Butler, senior lecturer on physiology in the Department of health environmental and investigator co-Minister of the laboratory; and researchers Dhananjay Tambe, Enhua Zhou Chan Young Park, Monirosadat Sadati, Park Jin-Ah, Bomi Gweon and Emil Millet.

Support for the study came from the Spanish Ministry of Science and Innovation (BFU2012-38146 FPU fellowship XS) and the Swiss National Science Foundation (PBEZP2-140047), the National Research Foundation of Korea (2012R1A6A3A03040450), the European Research Council (Grant Agreement 242993) Parker B. Francis (RK Fellowship), American Heart Association (13SDG14320004) and the National Institutes of Health (R01HL102373, R01HL107561).

"Propulsion and navigation within the advanced single layer sheet," Jae Hun Kim, Xavier Serra-Picamal, Dhananjay T. Tambe, Enhua H. Zhou, Chan Young Park, Monirosadat Sadati, Park Jin-Ah, Krishnan Ramaswamy, Bomi Gweon, Emil Millet, James P. Butler, Xavier Trepat, Jeffrey J. Fredberg, Nature of materials, online, June 23, 2013

Harvard School of Public Health

Please use one of the following formats to cite this article in your essay, paper, or report:

MLA

Harvard School of Public Health. "Understanding of complex diseases likely to improve following the unexpected discovery of the ways Cells Move." Medical news today. MediLexicon, international airport, 25 June 2013. Web.
June 25, 2013. APA

Please note: If no author information is provided, the source is cited instead.


?Understanding of complex diseases likely to improve following the unexpected discovery of the ways cells Move?

Please note that we publish your name, but we do not publish your email address. It is only used to notify you when your message is published. We do not use it for other purposes. Please see our privacy policy for more information.

If you write about specific drugs or operations, please are not professional health of the name by name.

All reviews are moderated before they can be included (to stop spam)

Contact our News editors

For any corrections of factual information, or to contact the editors, please use our feedback form.

Please send any new medical or health press releases to:

Note: any medical information published on this website are not intended as a substitute for informed medical advice and you should take any action before consulting professional health care. For more information, please read our terms and conditions.



View the original article here

Monday, June 17, 2013

Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab

Main Category: Cancer / Oncology
Also Included In: Neurology / Neuroscience
Article Date: 04 Jun 2013 - 0:00 PDT Current ratings for:
Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab
not yet ratednot yet rated
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (AvastinR), according to new research from The University of Texas MD Anderson Cancer Center.

The results of the study were presented at the annual meeting of the American Society of Clinical Oncology.

This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma. Half of the participants received bevacizumab while the other half received a placebo.

Glioblastoma is the most frequent and aggressive type of brain tumor. Despite slight gains, tumors pose a high risk of recurrence and are commonly fatal.

"In general, glioblastomas are heterogeneous and no drug has been found that benefits every patient," said Erik Sulman, M.D., Ph.D., assistant professor in MD Anderson's Department of Radiation Oncology and lead author of the study. "We wanted to determine which patients are most likely to benefit from bevacizumab and use that information to develop a diagnostic tool that can predict which patients may be good candidates for the drug."

Does mesenchymal gene expression predict response to bevacizumab?

Bevacizumab is a monoclonal antibody that binds to the protein vascular endothelial growth factor. It is a type of anti-angiogenesis agent and prevents the growth of new blood vessels that tumors need to develop.

Previous studies found some patients with recurring glioblastoma have longer progression-free survival and receive some lessening of symptoms with the drug.

The goal of this study was to investigate the ability of a particular type of gene expression signature to predict response to bevacizumab.

Mesenchymal expression, poor outcomes correlated

As part of RTOG 0825, 637 randomized patients submitted specimens for molecular analysis. The umbrella study data also included molecular stratification that measured the degree of gene enrichment. These genes are known to function in cancer cell invasion and in establishing new blood supply, a function which bevacizumab is designed to prevent.

Researchers observed a significant association between a lower mesenchymal signature and better survival in patients taking bevacizamab.

Based on this association and following the examination of 43 genes in total, researchers modeled a novel gene expression predictor of outcome specific to those in the bevacizumab group.

"One of the key things about this predictor is that it's designed to be used on standard, archival tumors found in most clinical pathology labs," Sulman said. "It doesn't require fresh tissue."

Next steps

The group plans ongoing studies to determine the extent to which this gene signature represents a predictive marker for bevacizumab use in newly diagnosed glioblastoma.

"We will use data from the remaining patients on the trial to validate these findings," Sulman said. "We hope the test will be validated and used as a diagnostic tool to select patients for initial treatment with bevacizumab. Then, we plan to look beyond glioblastoma to see if it could benefit other tumor types currently treated or in clinical trials with bevacizumab."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. Support sources for the study include Radiation Therapy Oncology Group (RTOG) grants U10 CA21661, CCOP grant U10 CA37422, Brain SPORE P50 CA127001 from the National Cancer Institute and Genentech, Inc.

Disclosures: Sulman received an honorarium from Merck.

In addition to Sulman other MD Anderson authors on the study include: Mark Gilbert, M.D., Paul Brown, M.D., Ritsuko Komaki, M.D. and Kenneth Aldape, M.D. Other authors include: Minhee Won, MA and James Dignam, Ph.D., Radiation Therapy Oncology Group; Deborah Blumenthal, M.D., Tel Aviv Sourasky Medical Center; Michael Vogelbaum, M.D., Ph.D., Cleveland Clinic; Howard Colman, M.D., Ph.D., Huntsman Cancer Institute; Robert Jenkins, M.D., Ph.D. and Kurt Jaeckle, M.D., Mayo Clinic; Arnab Chakravarti M.D., Ohio State University; Robert Jeraj, Ph.D., University of Wisconsin Madison; David Schiff, M.D., University of Virginia; James Atkins, M.D., Southeast Cancer Control Consortium; David Brachman, M.D., Arizona Oncology Services; Maria Werner-Wasik, M.D, Thomas Jefferson University Hospital; and Minesh Mehta, M.D., University of Maryland Medical Center.

University of Texas M. D. Anderson Cancer Center

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Texas M. D. Anderson Cancer Center. "Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab." Medical News Today. MediLexicon, Intl., 4 Jun. 2013. Web.
5 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here